Sobi finalized the acquisition of EmaCo AG, including Emapalumab and related assets, on 18 July 2019.

For more information on Sobi, please visit www.sobi.com

---

Novimmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand under “Light Chain Bioscience – A brand of Novimmune SA”.

For more information, please visit www.lightchainbio.com












TM & Copyright ©2019 EmaCo AG. All rights reserved.